Neoadjuvant Cytoreductive Treatment of Regionally Advanced Melanoma With BRAF/MEK Inhibition: Study Protocol of the REDUCTOR (Cytoreductive Treatment of Dabrafenib Combined With Trametinib to Allow Complete Surgical Resection in Patients With BRAF Mutated

The primary endpoint of the present trial is the percentage of patients in whom an R0 resection (microscopically radical) can be performed, as evaluated by pathologic examination. The secondary endpoints are recurrence-free survival, time to next treatment, and overall survival. Translational research will focus primarily on the assessment of treatment-induced changes in exome mutations within the tumor and changes in gene expression profiles.